{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"49"}],"units":"Participants"}],"description":"DAS modified included the DAS28 that consisted of a composite score of the following variables: TJC28, SJC28, CRP (mg/L), and PtGADA on a 0 to 100 mm VAS: 0 mm (no arthritis activity) to 100 mm (extremely active arthritis). DAS28 calculated as: DAS28-CRP = 0.56(square root of TJC28)+0.28(square root of SJC28)+0.36\\[ln(CRP +1)\\]+0.014(VAS)+0.96. For remission, DAS28 is \\<2.6. Percentage of participants = (number of participants with DAS28 remission) / (number of participants treated) \\* 100.","groups":[{"description":"Participants on background methotrexate therapy administered 1 x 1-mg baricitinib (LY3009104) capsule + 1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG000","title":"1 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 1-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG001","title":"2 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 1 x 4-mg baricitinib (LY3009104) capsule +1 identical placebo capsule, orally once daily for 12 weeks.","id":"OG002","title":"4 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 x 4-mg baricitinib (LY3009104) capsules orally once daily for 12 weeks.","id":"OG003","title":"8 mg Baricitinib (LY3009104)"},{"description":"Participants on background methotrexate therapy administered 2 placebo capsules, orally once daily for 12 weeks.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All participants who received any amount of study treatment in Part A.","reportingStatus":"POSTED","timeFrame":"Baseline up to 12 weeks","title":"Percentage of Participants Who Achieved a DAS28 Remission at 12 Weeks (Part A)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}